Basics Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). IPO Date: February 6, 2007 Sector: Healthcare Industry: Biotech Market Cap: $6.03B Activated in VL: True Average Daily Range Avg Daily Range: $3.54 | 2.60% Avg Daily Range (30 D): $5.39 | 1.78% Avg Daily Range (90 D): $7.93 | 2.46% Institutional Daily Volume Avg Daily Volume: .21M Avg Daily Volume (30 D): .29M Avg Daily Volume (90 D): .29M Trade Size Avg Trade Size (Sh.): 45 Avg Trade Size (Sh.) (30 D): 31 Avg Trade Size (Sh.) (90 D): 32 Institutional Trades Total Inst.Trades: 2,207 Avg Inst. Trade: $5.64M Avg Inst. Trade (30 D): $10.17M Avg Inst. Trade (90 D): $13.49M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $5.91M Avg Closing Trade (30 D): $10.56M Avg Closing Trade (90 D): $13.66M Avg Closing Volume: 32.15K         News May 10, 2025 @ 11:15 AM Madrigal Announces New Clinical Data Demonstrating... Source: N/A Apr 18, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: N/A Feb 26, 2025 @ 5:28 PM Madrigal Pharmaceuticals Stock Jumps On New Two-Ye... Source: Vandana Singh Feb 26, 2025 @ 4:27 PM Why Madrigal Pharmaceuticals Stock Is Soaring Toda... Source: Keith Speights Feb 12, 2025 @ 1:00 PM Madrigal Pharmaceuticals to Release Fourth-Quarter... Source: N/A Financials   TTM Q4 2024 FY 2024 Basic EPS $-3.32 $-2.59 $-21.9 Diluted EPS $-3.32 $-2.59 $-21.9 Revenue $ 137.25M $ 103.32M $ 180.13M Gross Profit $ 132.74M $ $ 173.9M Net Income / Loss $ -73.24M $ -59.42M $ -465.89M Operating Income / Loss $ -79.31M $ -67M $ -497.88M Cost of Revenue $ 4.51M $ $ 6.23M Net Cash Flow $ 83.63M $ -132.67M $ 5.1M PE Ratio     Splits Jul 25, 2016:   1:35